Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194531 · ClinicalTrials.gov registry record · Phase 4
Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer
A Phase 4 study, sponsored by Natera.
- Terminated
- Registry status
- Phase 4
- Development phase
- 59
- Enrollment target
NCT01194531 is a Phase 4 study that was terminated before completion, run by Natera. The registered enrollment target is 59 participants.
The verdict
NCT01194531, a Phase 4 study, was terminated before completion, sponsored by Natera.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 59 participants
- Enrollment target
Study Summary
Natera is recruiting patients for a research study evaluating pregnancy and implantation rates in women undergoing In Vitro Fertilization (IVF) and Preimplantation Genetic Screening (PGS). PGS is also referred to as Preimplantation Genetic Diagnosis (PGD) for aneuploidy. Healthy women undergoing IVF who are between the ages of 35 to 42 years are being recruited to participate in a randomized study. The purpose of this study is to determine whether PGS- testing of embryos created during IVF for chromosomal abnormalities, prior to transfer to the uterus- improves pregnancy and implantation rates in patients when compared to patients whose embryos are not tested. PGS will be conducted using 24 Chromosome Aneuploidy Screening with Parental Support from Natera. All subjects who qualify and enroll will receive discounted IVF medications (both TEST and CONTROL arms). If you become pregnant during the study, you will receive a small payment for providing information about your pregnancy and birth. If you are assigned to the TEST arm of the study you will receive free PGS.
Interventions
- DEVICE 24 Chromosome Aneuploidy Screening with Parental Support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01194531
The ClinicalTrials.gov registry entry for NCT01194531 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Natera, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 24 Chromosome Aneuploidy Screening with Parental Support is the first listed.
NCT01194531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01194531 about?
NCT01194531 is a clinical study titled "Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer". Natera is recruiting patients for a research study evaluating pregnancy and implantation rates in women undergoing In Vitro Fertilization (IVF) and Preimplantation Genetic Screening (PGS). PGS is also referred to as Preimplantation Genetic Diagnosis (PGD) for aneuploidy. Healthy women undergoing IV...
What is the current status of trial NCT01194531?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2010-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01194531?
The interventions under investigation include: 24 Chromosome Aneuploidy Screening with Parental Support (DEVICE).
Who is sponsoring clinical trial NCT01194531?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.